Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Sep 18, 2015 4:04pm

142 Views

Post# 24117035

RE:RE:RE:I had a dream last night

Well, G1945V sure has a case of the Friday blues. G1945V should re-watch the R&R webcast too. You do realize that there are some imminent announcements on the way in the next 1-2 weeks right? Yale Club, GCFF investor conferences next week. AGM on 9/30. Zenith is even presenting in Boston next week. Turn that frown upside down my friend.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale